Dear Editor, The International Prognostic Scoring System (IPSS) [1] , the gold standard for risk assessment in myelodysplastic syndromes (MDS), has been recently revised (IPSS-R). The authors proposed a new prognostic model including novel components: five cytogenetic prognostic subgroups with specific classification of a number of less common cytogenetic subsets [2, 3] ; the <5 % bone marrow blasts category was split between 0-2 % and >2-<5 %; depth of cytopenias at clinically relevant cut-points for haemoglobin level, platelet count, and absolute neutrophil count [2] . As the score [2] was established in MDS patients including all French-American-British classification subtypes [4] , the aim of this study was to apply the IPSS-R in Argentinean MDS patients classified according to the World Health Organization (WHO) classification [5] .
apply the IPSS-R in Argentinean MDS patients classified according to the World Health Organization (WHO) classification [5] .
We retrospectively analysed a cohort of 371 de novo MDS patients [6] diagnosed between 1981 and 2012. According to the WHO classification, 43 patients were classified as refractory cytopenia with unilineage dysplasia/ refractory anaemia with ringed sideroblasts, 17 as del(5q) syndrome, 201 as refractory cytopenia with multilineage dysplasia, 44 as RAEB type 1, and 66 as RAEB type 2. The median age was 70 (17-92) years with 72 % of patients above 60, the gender ratio was 1. Studied variables (gender and WHO classification, percentage of bone marrow blast, cytogenetic risk category, and depth of cytopenias according to the IPSS-R [2] ), and the IPSS [1] , IPSS-R (Fig. 1a-b) , and IPSS-R adjusted by age (Fig. 1c) [2] systems showed statistical differences for predicting both overall survival and leukemic evolution (see Electronic supplementary material, ESM). Patients were classified by the IPSS-R as very low (23 %), low (40 %), intermediate (15 %), high (14 %), and very high risk (9 %), with median survival of 125, 62, 44, 19, and 15 months (Fig. 1a) , and time to leukemic evolution (25 %) of >150, 131, 51, 6, and 5 months, respectively (Fig. 1b) . The proposed IPSS-R defines a new intermediate risk group mainly composed by patients from the intermediate-1 IPSS risk category (84 %, 47/56) and allowed us to identify 7 % (11/150) of patients that were shifted from the intermediate-1 risk group into the high IPSS-R risk group.
Although limit age of 60 years did not show statistical differences for predicting survival, our results confirm that younger good risk patients have significantly better prognosis than elderly counterparts (very low/low risk patients: 125 vs. 7, 8] . The proposed formula for an age-adjusted categorization [2] helped us to identify 19 % (28/147) of short surviving patients among low risk IPSS-R patients with a median survival of 34 months (Fig. 1d) . These patients showed, among relevant parameters, a gender ratio M/F of 3.0, a median age of 81 years, 2.5 % of BM blasts, and 9.1 g/dL of haemoglobin level; 12 (43 %) presented an abnormal karyotype and 17 died, including 6 patients with previous leukemic progression.
It can be concluded that the IPSS-R system is simple to use since includes accessible variables showing a good reproducibility, effectiveness in predicting clinical outcome, and a refinement of the intermediate risk category in our WHO classified series. Fig. 1 Prognostic relevance of the IPSS-R group of risk in the Argentinean cohort of MDS patients classified by WHO. Kaplan-Meier plots for a survival according to the IPSS-R, b progression to acute myeloid leukaemia (AML), c survival related to their respective age-adjusted 64 months, p=0.014), while the age at diagnosis has no impact on disease outcome for higher risk patients [1 2 IPSS-R group of risk for the overall population, and d for the very low/ low risk group of patients. Number of patient and median overall survival or the time to 25 % to AML evolution for each group of risk are shown , , Ethical statement All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study.
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